US:
UK:
JAPAN:
- Report code : CMI-422
- Industry : Clinical Diagnostic
- Published On : Feb 2020
- Pages : 175 Pages
- Format :
Press Release: HIV Diagnostics Market to Surpass US$ 6.6 Billion by 2027
Press Release: HIV Diagnostics Market to Surpass US$ 6.6 Billion by 2027
HIV diagnostics plays a major role in HIV prevention, treatment, care, and other support services. The diagnosis of HIV include testing services in health-care facilities, and wide range of community-based approaches along with HIV self-testing.
The global HIV diagnostics market was valued at US$ 3,050.8 million in 2018, and is expected to exhibit a CAGR of 9.2% over the forecast period (2019-2027).
Figure 1. Global HIV Diagnostics Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2020)
Rising government initiatives are expected to boost growth of the HIV diagnostics market
HIV diagnostics market is expected to witness significant growth, owing to rising government initiatives, in order to control the HIV infection. For instance, in April 2017, Ministry of Health and Family Welfare, Government of India, launched ‘Test and Treat Policy for HIV’ policy, which is expected to improve longevity and quality of life of those infected with HIV. Moreover, in 2017, Ministry of Health, Sri Lanka initiated National HIV/STI Strategic Plan (NSP) Sri Lanka 2018-2022. This strategic plan include five objectives, which will support NSP’s vision to make country free from new HIV infections, discrimination, and AIDS related deaths.
Increasing demand for home testing HIV diagnosis is encouraging key manufacturers to focus on developing portable, easy-to-use, and rapid diagnosis test. This, in turn, is expected to boost the market growth. For instance, in November 2018, Atomo Diagnostics’ Atomo HIV Self-Test was approved for sale in Australia by the Therapeutic Goods Administration (TGA). It is the first and only diagnostic self-test for HIV to receive approval from Australia’s national regulator.
HIV diagnostics market is expected to witness significant growth, owing to increasing adoption of agreement and collaborations strategies by the market players. For instance, in September 2019, Mylan N.V. and Atomo Diagnostics entered into partnership. Under the partnership Mylan gained commercialization rights for Atomo’s HIV rapid diagnostic in Africa, Asia, Middle East, the Commonwealth of Independent States (CIS), and Latin America.
Rising number of HIV cases, which are undiagnosed or late diagnosed are driving demand for HIV diagnostics, which is further expected to bolster HIV diagnostics market growth over the forecast period. For instance, according to the European Centre for Disease Prevention and Control (ECDC) report 2017, around 51% of all HIV cases were diagnosed late, and around 28% had advanced HIV infection, when diagnosed in the Europe in 2015. Moreover, the proportion of those late diagnosis was over 50% in nine European countries, which include Austria, Estonia, Greece, Italy, Latvia, Lithuania, Romania, Slovenia, and Sweden.
Figure 2. Global HIV Diagnostics Market Share (%), by Product Type, 2019 and 2027
Source: Coherent Market Insights Analysis (2020)
HIV Diagnostics Market - Regional Analysis
North America held a dominant position in the global HIV diagnostics market in 2018, owing to increasing product approval in the region. For instance, in November 2019, Vela Diagnostics received de novo authorization by the U.S. Food and Drug Administration (FDA) for its Sentosa SQ HIV-1 Genotyping Assay developed for detection of HIV-1 genomic drug resistance mutations (DRMs). Moreover, in May, 2019, Abbott Laboratories received the World Health Organization's Prequalification approval (WHO PQ) for m-PIMA HIV-1/2 VL, the first point-of-care viral load diagnostic test. The portable molecular point-of-care test is designed specifically for usage in resource-limited settings. The prequalification status qualifies the product for purchase by agencies of the United Nation.
Moreover, Europe is expected to witness significant growth in the HIV diagnostics market during the forecast period, owing to rising product launches by the key players. For instance, in July 2018, Abbott Laboratories, launched m-PIMA HIV-1/2 VL, the first point-of-care viral load diagnostic test at the International AIDS Conference, held in Amsterdam in 2018.
Key Players
Major players operating in the global HIV diagnostics market include Abbott Laboratories, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myres Squibb, Janssen Therapeutic, QIAGEN N.V., and ViiV Healthcare Ltd.
Acquired Immunodeficiency Syndrome (AIDS) is caused by human immunodeficiency virus (HIV). HIV diagnosis tests are carried out to detect the presence of the virus. HIV diagnosis can be performed by blood test, saliva test, viral load test, though the most efficient test results are achieved by Enzyme Linked Immunosorbent Assay (ELISA) test initially and Western Bloat Method. ELISA test, which is enzyme linked immunosorbent assay, uses the antibodies to identify the substance and the western blot technique is used to detect anti –HIV antibodies in the human serum sample.
Market Dynamics
Increasing prevalence of HIV are expected to propel global demand for HIV diagnostics over the forecast period. For instance, according to the UNAIDS 2019 report, number of HIV cases increased from 37.2 million to around 37.9 million globally, from the year 2017 and 2018 respectively. Moreover, according to the UNAIDS 2019 report, around 1.7 million new cases of people globally living with HIV was reported in 2018.
Increasing collaborations and acquisitions by the market players are expected to drive the market growth over the forecast period. For instance, in 2016, Abbott Laboratories acquired Alere Inc, a manufacturer of rapid point-of-care diagnostic tests. The acquisition was done to add tests products for infectious diseases such as HIV, tuberculosis, malaria, influenza to Abbott Laboratories’ suite of products for testing genetic mutations and to boost diagnostics offerings of the company.
Moreover, rising product launches by the market players is expected to propel the market growth over the forecast period. For instance, in 2014, BD Biosciences, a segment of BD (Becton, Dickinson and Company) launched BD FACSPresto near patient CD4 counter system for HIV/AIDS patients, which provide lymphocytes and hemoglobin (Hb) concentration in blood samples to stage and monitor HIV/AIDS patients. Moreover, in July 2017, bioLytical Laboratories launched INSTI HIV Self-Test in pharmacies across the Netherlands, thereby providing access to HIV tests for early diagnosis. The INSTI product line is 99% accurate and provides test results in 60 seconds or less. Moreover, the company also offers contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 34 market data tables and 25 figures on "HIV Diagnostics Market - Global forecast to 2027”.
Asia Pacific Intelligence Center (India): 